HDFC AMC Q1: consol PAT ₹837 Cr up 12% YoY, revenue +14%; opex trims margins

HDFC AMC reported consolidated PAT of ₹837.13 Cr for Q1 FY27, up ~12.0% YoY (from ₹747.55 Cr) on revenue from operations of ₹1,099.72 Cr, up ~13.6% YoY — steady double-digit growth tracking equity AUM buoyancy, but with profit growth trailing topline. The headline sequential jump (+34.5% QoQ vs ₹622.66 Cr) is largely an other-income artifact: treasury/mark-to-market other income was ₹262.84 Cr this quarter against just ₹11.55 Cr in the Mar-26 quarter, so the QoQ read flatters the operating picture. Standalone PAT (₹838.36 Cr) is effectively identical — the IFSC subsidiary is immaterial, so the two bases tell the same story.

The cleaner YoY lens shows margin compression at the core. Total expenses rose ~27% YoY (₹215.48 → ₹273.54 Cr), well ahead of the ~14% revenue growth, driven by employee benefit expenses up ~31% (₹109.23 → ₹143.61 Cr) and other expenses up ~22% — the team-expansion/investment spend flagged by the Street. Core operating margin (rev-from-ops less expenses) slipped to ~75.1% from ~77.7%, and net margin on total income eased to ~61.4% from ~62.2%. PBT grew ~10.5%; a slightly lower effective tax rate (23.1% vs 24.2%) lifted PAT growth back to ~12%.

The stock went into the print at ₹2,735.7, up 4.3% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.

Against the prior concall, management had given no quantitative guidance but signalled continued investment in people, technology and distribution with costs 'broadly in line with the business' and the new TER regulations as 'not material' — this print is consistent with that investment-led playbook, though cost growth actually ran ahead of revenue this quarter. No brokerage consensus PAT figure was locatable pre-print; the qualitative expectation was a continuation of FY26's ~28% profit momentum, which this ~12% YoY print does not match, reflecting a tougher other-income comparison and cost build-out rather than core weakness.